Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 235 pages

Showing 201 - 235


skin cancer

Surgical Treatment for Metastatic Melanoma of the Liver Increases Overall Survival in Select Group of Patients

Surgical resection markedly improved survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the Journal of the American College of Surgeons. These results mark a departure for melanoma, which is most often...

issues in oncology
skin cancer

Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475

Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego. When the protein...

skin cancer
kidney cancer

Antibody Could Be Used to Target Tumor-Enhancing Protein, Study Shows

In a phase I study published in PLOS ONE, treating patients with advanced melanoma and kidney cancer with an antibody that targets a tumor-enhancing protein was found to have an acceptable safety profile and showed preliminary evidence of antitumor activity. The findings by Morris et al shed light...

skin cancer

Biomarker May Predict Response to Ipilimumab in Advanced Melanoma

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab (Yervoy), according to a study by Yuan et al published in Cancer Immunology Research....

skin cancer

FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations

The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...

skin cancer

Additional Interim Data for Lambrolizumab Show Survival Benefit for Patients With Advanced Melanoma

Additional data for the investigational anti–PD-1 immunotherapy lambrolizumab (MK-3475) were presented yesterday at the 10th International Congress of the Society for Melanoma Research in Philadelphia. In patients with advanced melanoma, lambrolizumab demonstrated an estimated 1-year overall...

issues in oncology
skin cancer
issues in oncology

New Biomarker May Help Guide Treatment of Melanoma Patients

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held...

skin cancer
issues in oncology

New Molecular Diagnostics Platform Enables Rapid Detection of BRAF V600 Mutations

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented at the AACR-NCI-EORTC International...

breast cancer
skin cancer

Potential New Drug Effective in Breast Cancer and Melanoma Resistant to Targeted Therapies

LEE011, an investigational small-molecule inhibitor of cyclin-dependent kinase (CDK) 4/6, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, according to findings presented at the AACR-NCI-EORTC...

skin cancer
issues in oncology
survivorship

Intervention Program Improves Sun Protection Practices Among Children of Melanoma Survivors

Children of melanoma survivors were more likely to wear hats and reapply sunscreen after receiving a multimedia informational program designed specifically for them. These new findings were included in research published in Cancer Epidemiology, Biomarkers & Prevention. A team of researchers...

skin cancer

PDK1 Gene Identified as New Target for Melanoma Treatment

According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...

skin cancer

FDA Grants Priority Review Designation for Dabrafenib/Trametinib Combination in Metastatic Melanoma

GlaxoSmithKline recently announced that the U.S. Food and Drug Administration has granted Priority Review designation to its supplemental New Drug Applications for the combined use of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic ...

skin cancer

Enhanced Treatment, Surveillance Needed for Certain Melanoma Patients to Prevent Secondary Cancers, Researchers Say

Researchers at Moffitt Cancer Center in Tampa, Florida, suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy with other inhibitors, especially as they become...

skin cancer

Age-Related Variations Observed in Treatment of Melanoma

Age-related variations in the treatment of melanoma were observed in a study of melanoma and its management in the elderly compared to younger patients, according to a study by Dragos Ciocan, MD, of the Unité d’Aide Méthodologique, Hôpital Robert Debré, France, and...

skin cancer

Enhanced Treatment, Surveillance Needed for Patients With BRAF-Mutant Melanoma to Prevent Secondary Cancers

Researchers at Moffitt Cancer Center suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF inhibitor therapy with other inhibitors, especially as they become more widely used....

skin cancer

Mechanism Offers Promising New Approach for Harnessing the Immune System to Fight Cancer

Scientists at St. Jude Children’s Research Hospital have discovered a way to target the immune system to shrink or eliminate tumors in mice without causing autoimmune problems. Researchers also found evidence that the same mechanism may operate in humans. The study was published online today...

skin cancer
head and neck cancer

Omega-3 Fatty Acids May Aid in Treatment and Prevention of Skin and Oral Cancers

Omega-3 fatty acids, contained in oily fish such as salmon and trout, selectively inhibit growth and induce cell death in early- and late-stage oral and skin squamous cell carcinomas, according to new research from scientists at Queen Mary, University of London. The findings were published online...

skin cancer

Nonsentinel Lymph Node Positivity Appears to be Significant Prognostic Factor in Patients with Melanoma

Nonsentinel lymph node positivity appears to be a significant prognostic factor in patients with stage III melanoma, according to a study by Anna M. Leung, MD, of the John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California, and colleagues. The study was published...

skin cancer
skin cancer

Intratumoral IL-12 Injections Shrink Melanoma and Merkel Cell Tumors

Intratumoral injections of plasmid DNA encoding interleukin-12 (IL-12), facilitated in its delivery by electroporation, results in tumor regression in patients with both metastatic melanoma and Merkel cell carcinoma, according to findings reported at the 2013 World Cutaneous Malignancies Congress...

skin cancer

Surgeons Report Melanoma Recurs after 10 Years in More than 6% of Patients

Recurrence of melanoma skin cancer 10 or more years after initial treatment is more common than previously thought, occurring in more than 1 in 20 patients. However, according to a new study, these patients tend to live longer after their cancer returns than patients whose melanoma recurs in the...

skin cancer

Among White Adolescents and Young Adults with Melanoma, Males Have Higher Mortality Than Females

Melanoma is the third most common cancer among adolescents and young adults, but few studies have explored the survival differences by sex in this population. A new study published in JAMA Dermatology sought to determine whether long-term survival varied between white male and female...

skin cancer

Mortality Appears to be Higher for Patients with Thicker Single Primary Melanomas than for Thicker Multiple Primary Melanomas

Although overall mortality rates due to single primary melanomas and multiple primary melanomas appear to be similar, relative mortality for thicker single primary melanomas appears to be greater than that for thicker multiple primary melanomas, according to a study by Anne Kricker, PhD, of the...

skin cancer
issues in oncology

DNA Sequencing Reveals Mucosal Melanoma's Genetic Fingerprint

Scientists have found a molecular "bullseye" for a rare form of melanoma, opening up opportunities for novel targeted treatment, according to new research published in the Journal of Pathology. Whole genome and whole exome sequencing carried out at Cancer Research UK’s Paterson Institute for ...

skin cancer

ASCO 2013: Selumetinib Significantly Improves Progression-free Survival for Patients with Advanced Melanoma of the Eye

Progression-free survival was significantly improved for patients with metastatic melanoma of the eye (uveal melanoma) treated with selumetinib, according to the final analysis of data from a phase II crossover study presented at the 2013 ASCO Annual Meeting (Abstract CRA9003). Progression-free...

skin cancer

ASCO 2013: Nivolumab Produces Durable Responses in Patients with Stage IV Melanoma

Long-term follow-up results from an expanded phase I study indicate that nivolumab produced long-lasting responses in patients with stage IV melanoma. Overall, 33 out of 107 patients (31%) treated with five different doses of nivolumab experienced tumor shrinkage of at least 30% and responses were...

skin cancer

ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma

Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...

skin cancer

ASCO 2013: Anti–PD-1 Antibody Produces Durable, Ongoing Response in Patients with Advanced Melanoma

Preliminary results of an ongoing trial suggest that the anti–PD-1 antibody lambrolizumab has significant antitumor activity in patients with advanced melanoma and is well tolerated. The data were presented by Antoni Ribas, MD, PhD, Professor of Hematology/Oncology and Surgery, and Director...

skin cancer

FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer

The U.S. Food and Drug Administration today approved two new drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), for patients with advanced or unresectable melanoma, the most dangerous type of skin cancer. Dabrafenib, a BRAF inhibitor, is approved to treat patients with melanoma whose tumors...

skin cancer

Inflammatory Bowel Disease Raises Risk of Melanoma

Patients with inflammatory bowel disease are at higher risk of melanoma, reported researchers at Mayo Clinic. Researchers found that inflammatory bowel disease is associated with a 37% greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in...

skin cancer

ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma

Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...

skin cancer
skin cancer

Researchers Observe an Increased Risk of Cancer in People with History of Nonmelanoma Skin Cancer

A prospective study by researchers at Brigham and Women's Hospital observed an association between risk of second primary cancer and history of nonmelanoma skin cancer in white men and women. The researchers found that people with a history of nonmelanoma skin cancer had a modestly increased risk...

skin cancer

Breakthrough Therapy Designation for Lambrolizumab for the Treatment of Advanced Melanoma

Merck has announced that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck’s investigational antibody therapy targeting the programmed death receptor (PD-1) that...

breast cancer
skin cancer

New Imaging Agent Enables Better Cancer Detection, More Accurate Staging

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye technetium Tc-99m...

skin cancer

Amgen Announces Results of Phase III Talimogene Laherparepvec Trial in Late-stage Melanoma

Amgen has announced results from a phase III trial evaluating the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Talimogene...

skin cancer

New Website Raises Awareness of Uveal Melanoma and the Importance of Prognostic Testing

Launch of a website created to educate newly diagnosed patients, their families, and health-care providers about uveal melanoma, was announced recently by Castle Biosciences, Inc, a developer of prognostic tests for rare cancers. The website, MyUvealMelanoma.com, addresses the treatment of uveal...

Advertisement

Advertisement



Advertisement